Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals Inc.

Denta Water and Infra Solutions Limited ( ($IN:DENTA) ) has issued an announcement. Denta Water and Infra Solutions Limited reported audited standa...

Current Quarter	$-0.42	Next Quarter	$-0.7
Current Year	$-2.01	Next Year	$-1.81
QoQ Growth	-66.7%	YoY Growth	+10.0%
3Y EPS CAGR	+13.4%	Target Price	$18.71
Consensus	Buy	Upside	+41.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$13.23	+0.30%	165.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$13.23	+0.3%	165.55K
3
4
5
6

ENTA

ENTA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Enanta Pharmaceuticals Inc. Data in Excel

Get Enanta Pharmaceuticals Inc. Data in Excel